Fluvoxamine

Pioneering Phase III Clinical Trial Investigates Multiple Potential Long-COVID Treatments

Retrieved on: 
Thursday, November 2, 2023
Technology, Other Health, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Software, Science, Clinical Trials, EDC, Incidence, Electronic data capture, McMaster University, PLS, Digestion, Metformin, Infection, Inflammation, DSM-IV codes, Cell, Long COVID, COVID, Disease, Fluvoxamine, COVID-19, SSRI, EHR, Patient, Electronic health record, Fatigue, Pharmaceutical industry

The trial was designed by researchers at McMaster University in Hamilton, Canada, and is aimed at addressing the persisting challenges posed by Long-COVID.

Key Points: 
  • The trial was designed by researchers at McMaster University in Hamilton, Canada, and is aimed at addressing the persisting challenges posed by Long-COVID.
  • As a multi-center study beginning with 1,500 patients, the trial will rigorously assess the efficacy of multiple potential treatment options – beginning with fluvoxamine and metformin – in alleviating the symptoms associated with Long-COVID.
  • The trial will leverage state-of-the-art data management via an EDC developed by Yonalink, to ensure the highest caliber of data integrity.
  • The new approach seeks to swiftly identify effective Long-COVID-19 treatments and assess comparative efficacy without compromising the rigorous standards of a randomized clinical trial.

Parsemus Foundation: Metformin Drastically Reduces COVID Hospitalization, Study Shows

Retrieved on: 
Thursday, August 18, 2022
Health, Consumer, Diabetes, Infectious Diseases, Clinical Trials, Pharmaceutical, Hispanic, Parsemus Foundation, Â, The New England Journal of Medicine, Lissner, University, Inflammation, Metformin, Death, Assistant, COVID, Research, COVID-19, Foundation, MTOR, Solution, Fluvoxamine, Health, Pharmaceutical industry, Hospital

The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.

Key Points: 
  • The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.
  • But you dont know whether its just coincidence until you go back to the beginning, with a rigorous randomized trial.
  • Parsemus Foundation was joined by two larger foundations also eager to see low-cost, globally-accessible medications put to the test.
  • More information on the Parsemus Foundation and the work presented here can be found at: https://www.parsemus.org/humanhealth/covid-19/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005438/en/

Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China

Retrieved on: 
Thursday, March 3, 2022
Purging disorder, Security (finance), Degenerative disease, Neutropenia, Urine, Enoxacin, U.S. Securities and Exchange Commission, Tongue, Hypertension, ALS, CYP1A2, News, FDA, Therapy, Drug development, Anaphylaxis, LinkedIn, Company, Development, Food, Caregiver, Jaundice, Water, Methoxsalen, Tablet, Vomiting, Fluvoxamine, Cough, Clobazam, Nausea, Fatigue, CNS, Fever, Mexiletine, Tiabendazole, Seizure, Riluzole, NASDAQ, Allergy, Lennox–Gastaut syndrome, Viscosity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, HIV disease progression rates, Liver, Central nervous system, Safety, Weakness, Abdominal pain, Vemurafenib, SZSE, Hepatotoxicity, Ciprofloxacin, GLOBE, Amyotrophic lateral sclerosis, Pharmaceutical industry

Around 85% of ALS patients suffer from a progressive loss of bulbar functionality.1 Swallowing food and liquids becomes more difficult over time.

Key Points: 
  • Around 85% of ALS patients suffer from a progressive loss of bulbar functionality.1 Swallowing food and liquids becomes more difficult over time.
  • This agreement with Haisco will allow ALS patients in China to access EXSERVAN, a riluzole oral film, which will provide a meaningful treatment option to those who have to discontinue their treatment because of difficulties swallowing a tablet.
  • Pursuant to the agreement, Haisco will lead the regulatory and commercialization activities for EXSERVAN in China.
  • EXSERVAN, an oral film formulation of riluzole, was developed by Aquestive using its PharmFilminnovative drug delivery technology.

FLCCC Tells Children’s Health Defense: World’s Leading ICU Doctor Files Lawsuit Against Hospital System After Being Barred from Administering Proven COVID-19 Treatments

Retrieved on: 
Wednesday, November 10, 2021
Mortality, ICU, Ivermectin, Complaint, First Nations in Ontario, Evidence-based medicine, Eastern Virginia Medical School, Critical care, Circuit court, Sentara Norfolk General Hospital, Fluvoxamine, Division, Hospital, Isabella Tree, COVID, COVID-19, Research, Clinical study design, Wisconsin circuit courts, Patient, GLOBE, City, Children's Health Defense, Hippocratic Oath, Death, Physician, United Nations, Ill, FDA, FLCCC, Pharmaceutical industry

Corporations and faceless bureaucrats should not be allowed to interfere with doctor-patient decisions, especially when it can result in harm or death."

Key Points: 
  • Corporations and faceless bureaucrats should not be allowed to interfere with doctor-patient decisions, especially when it can result in harm or death."
  • according to Paul Marik, MD, chief, Division of Pulmonary & Critical Care Medicine, Eastern Virginia Medical School, who practices in the Sentara Norfolk General Hospital.
  • I refuse to watch another patient die from COVID-19 knowing that I was not allowed to give them proven treatments that could have saved their life.
  • Their MATH+ Hospital Treatment Protocol introduced in March 2020, has saved thousands of patients who were critically ill with COVID-19.

TTUHSC El Paso Part of NIH Trials to Find Effective COVID-19 Treatments

Retrieved on: 
Tuesday, November 2, 2021
Foster School, Research, Fluvoxamine, University Medical Center of El Paso, Failure, Hearing, Ivermectin, Paul L. Foster School of Medicine, Patient, Fluticasone, FDA, Pneumonia, Eye, Emergency medicine, National, COVID-19, Rhinitis, Inflammation, Psychiatry, Texas Tech University Health Sciences Center El Paso, News, University, GLOBE, Transfusion-related acute lung injury, University Medical Center, Department, Reading, Asthma, Animal, Pharmaceutical industry

The first project is TTUHSC El Paso's collaboration in ACTIV-6, a national trial of existing drugs to determine their effectiveness in treating COVID-19.

Key Points: 
  • The first project is TTUHSC El Paso's collaboration in ACTIV-6, a national trial of existing drugs to determine their effectiveness in treating COVID-19.
  • "At TTUHSC El Paso, we're researching different aspects of COVID-19," said Dr. Michelson, who's also medical director of the emergency department at University Medical Center of El Paso.
  • "From diagnostic tests to therapeutic trials, our research will benefit our patients, the local community, and if we're successful, the world."
  • "The fact that El Pasoans have access to treatments that are part of national clinical trials is important," Dr. Michelson said.

Recent Fluvoxamine COVID benefits discovered using Cytel-designed platform trial

Retrieved on: 
Monday, September 13, 2021
Health, Infectious Diseases, Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology

There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.

Key Points: 
  • There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.
  • Platform trials, such as those used to test fluvoxamine, allow multiple therapies to be tested using a single study design with a shared control arm.
  • Dr. Wathen is well known for his work in platform trials having helped design several platform trials previously and his contributions and help in designing the I-SPY 2 trial, a platform trial that transformed breast cancer research.
  • The TOGETHER TRIAL may also open the door for platform trials to become a much more widespread research study design.

New report describes positive results of generic drug in treating COVID

Retrieved on: 
Monday, February 1, 2021
Selective serotonin reuptake inhibitors, Antidepressants, Health sciences, Occupational safety and health, Ethers, Fluvoxamine, Psychoactive drugs, Health, Coronavirus disease

"Repurposed drugs always have had the potential to be the fastest and least expensive way out of this pandemic.

Key Points: 
  • "Repurposed drugs always have had the potential to be the fastest and least expensive way out of this pandemic.
  • In this study, fluvoxamine was again shown to be 100% effective in the early treatment of COVID.''
  • In addition, after two weeks, none of the treatment group had any COVID symptoms while 60% of the group who declined the drug had one or more COVID symptoms.
  • CETF is funding a Phase 3 clinical trial to examine the efficacy of using fluvoxamine for the early treatment of COVID.

Fluvoxamine Data Unveiled as Promising Early Treatment in Patients with Mild COVID-19

Retrieved on: 
Tuesday, October 6, 2020
Health, Articles, Selective serotonin reuptake inhibitors, Clinical research, Pharmaceutical industry, Ethers, Fluvoxamine, Drug discovery, Clinical trial, Coronavirus disease, COVID-19 drug repurposing research, COVID-19 drug development

The trial results indicated that fluvoxamine, if given early in the course of COVID-19, significantly reduced the likelihood of hospitalization.

Key Points: 
  • The trial results indicated that fluvoxamine, if given early in the course of COVID-19, significantly reduced the likelihood of hospitalization.
  • Fluvoxamine a repurposed drug has been around since 1983 and could prevent COVID-19 patients from developing more severe symptoms.
  • COVID-19 Early Treatment Fund is the sole or primary sponsor of several other clinical trials that are led by leading scientific researchers.
  • Once funded, outpatient trials could identify an effective early treatment within just a few months.

Upsher-Smith Launches Fluvoxamine Maleate Tablets

Retrieved on: 
Friday, January 10, 2020
Selective serotonin reuptake inhibitors, RTT, Psychoactive drugs, Medicine, Health, Ethers, Fluvoxamine, Depression, Antidepressants, MedWatch, Adverse effect, Obsessive–compulsive disorder

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders.

Key Points: 
  • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders.
  • Fluvoxamine maleate is not approved for use in pediatric patients except those with obsessive compulsive disorder.
  • Please refer to the full Prescribing Information, including Boxed Warning for Fluvoxamine Maleate Tablets here .
  • You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch .